8-K filed Jun 17, 2026 at 07:35 ET
Dyne Therapeutics expanded its Hercules Capital debt facility to $400M via a Second Amendment, borrowing an additional $50M on closing. The amendment adds two new $50M tranches and increases the final tranche by $25M, while reducing the minimum cash covenant from 60% to 40% of outstanding obligations and pushing the testing date from January 2027 to July 2027 (extendable to 2028). Outstanding debt post-borrowing is $200M, with up to $200M in additional undrawn tranches available upon milestones or lender approval. The move extends cash runway for a pre-revenue biotech with a $3.0B market cap and 85% analyst buy rating, but adds leverage and secured IP collateral, net neutral for the credit story.